ArriVent BioPharma (AVBP) Interest Expenses (2023 - 2026)
ArriVent BioPharma (AVBP) posted Interest Expenses of $40.1 million for Q1 2026, up 23739.88% sequentially from $168000.0 in Q4 2025, and up 35.65% YoY from $29.5 million in Q1 2025.
ArriVent BioPharma (AVBP) Interest Expenses (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Interest Expenses for 4 years, with the latest figure at $40.1 million in Q1 2026.
- Quarterly Interest Expenses rose 35.65% year-over-year to $40.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.1 million (up 35.65% YoY) and the FY2025 annual result came in at $31.7 million, down 37.09% from the prior year.
- Interest Expenses advanced to $40.1 million in Q1 2026 per AVBP's latest filing, from $168000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $44.1 million in Q4 2023 and troughed at $168000.0 in Q4 2025.
- A 4-year average of $28.9 million and a median of $33.0 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2026: Interest Expenses slumped 98.73% in 2024, then surged 35.65% in 2026.
- Over 4 years, Interest Expenses stood at $44.1 million in 2023, then plunged by 98.73% to $561000.0 in 2024, then plunged by 70.05% to $168000.0 in 2025, then soared by 23739.88% to $40.1 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $40.1 million, $168000.0, and $28.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 115.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.10 Mn |
| Jun 30, 2026 | 115.10 Mn |
| Mar 31, 2026 | 40.05 Mn |
| Mar 31, 2026 | 40.05 Mn |
| Dec 31, 2025 | 168,000.00 |
| Dec 31, 2025 | 168,000.00 |
| Sep 30, 2025 | 28.48 Mn |
| Sep 30, 2025 | 28.48 Mn |
| Jun 30, 2025 | 37.02 Mn |
| Jun 30, 2025 | 37.02 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Dec 31, 2024 | 561,000.00 |
| Dec 31, 2024 | 561,000.00 |
| Sep 30, 2024 | 42.87 Mn |
| Sep 30, 2024 | 42.87 Mn |
| Jun 30, 2024 | 33.13 Mn |
| Jun 30, 2024 | 33.13 Mn |
| Mar 31, 2024 | 32.96 Mn |
| Mar 31, 2024 | 32.96 Mn |